Fecal microbiota transplant for treatment of C. difficile infection, the most common cause of diarrhea in hospitalized patients, might be suitable for treatment of high-risk immunocompromised patients, according to a retrospective study of 66 cases from 16 centers in North America. Data presented at the ACG Annual Scientific Session point to a cure rate of 89% in high-risk populations, consistent with studies of other populations, and the study found "fecal transplant is safe in this population, and importantly there were no infectious complications," said researcher Colleen Kelly.

Related Summaries